BUSINESS

US FDA Gives 1st Nod for Lenvima/Keytruda Combo as 2nd-Line Therapy for Endometrial Carcinoma

September 19, 2019
The US FDA approved on September 17 the combination therapy of Eisai’s multi-kinase inhibitor Lenvima (lenvatinib) plus US Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of patients with advanced endometrial carcinoma, marking the first approval for the combo, the…

To read the full story

Related Article

BUSINESS

By Kazuhiro Chiboshi

Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…

By Eric Persoff

Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…

By Reiji Anasako

The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…